
Aethlon Medical, Inc. was very bullish in the pre-market session. The company received breakthrough device designation from the FDA for their Hemopurifier, which is used for the treatment of cancer. According to a press release from the company, the device is a “first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses”. Here’s a recap of what happened.